Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation-Reference-Cited by-同舟云学术

Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation

Published:2019-12-20 Issue:1 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Kidd James M.¹,Sakon Colleen M.²,Oleksiuk Louise-Marie³,Cies Jeffrey J.⁴,Pettit Rebecca S.⁵,Nicolau David P.¹,Kuti Joseph L.¹

Affiliation:

1. Center for Anti-Infective Research and Development, Hartford Hospital, Harford, Connecticut, USA

2. Indiana University Health, Indianapolis, Indiana, USA

3. UPMC Presbyterian Shadyside Hospital, Pittsburgh, Pennsylvania, USA

4. St. Christopher’s Hospital for Children, Philadelphia, Pennsylvania, USA

5. Riley Hospital for Children, Indianapolis, Indiana, USA

Abstract

Adults with cystic fibrosis (CF) frequently harbor Staphylococcus aureus , which is increasingly antibiotic resistant. Telavancin is a once-daily rapidly bactericidal antibiotic active against methicillin-, linezolid-, and ceftaroline-resistant S. aureus . Because CF patients experience alterations in pharmacokinetics, the optimal dose of telavancin in this population is unknown.

Funder

Cumberland Pharmaceuticals

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01914-19

Reference30 articles.

1. Cystic Fibrosis Foundation. 2017. Patient registry annual data report. Cystic Fibrosis Foundation Bethesda MD. https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2017-Patient-Registry-Annual-Data-Report.pdf. Accessed 4 September 2019.

2. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients

3. Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis

4. A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study

5. Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bayesian prediction-based individualized dosing of anti-methicillin-resistant Staphylococcus aureus treatment: Recent advancements and prospects in therapeutic drug monitoring;Pharmacology & Therapeutics;2023-06

2. Defining the Importance of Age-Related Changes in Drug Clearance to Optimizing Aminoglycoside Dosing Regimens for Adult Patients with Cystic Fibrosis;European Journal of Drug Metabolism and Pharmacokinetics;2021-12-09

3. COVID-19 Drug Repositioning: Present Status and Prospects;Modeling, Control and Drug Development for COVID-19 Outbreak Prevention;2021-11-02

4. Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review;International Journal of Antimicrobial Agents;2021-09

5. Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses;Clinical Pharmacokinetics;2021-01-15